Traci Kreifels, APRN
Family Medicine · Lincoln, NENPI 1578057071
Payments from drug & device makers
Across 504 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$907
- Lilly USA, LLC$852
- AstraZeneca$558
- Pfizer$503
- Esperion Therapeutics, Inc.$480
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,33399%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $1,035 |
| Novo Nordisk | 68 | $907 |
| Lilly USA, LLC | 78 | $852 |
| AstraZeneca | 18 | $558 |
| Pfizer | 32 | $503 |
| Esperion Therapeutics, Inc. | 43 | $480 |
| Amgen | 33 | $480 |
| Astellas Pharma US Inc | 13 | $462 |
| Bayer | 28 | $455 |
| Boehringer Ingelheim | 26 | $375 |
| Novartis | 11 | $203 |
| Biohaven Pharmaceuticals, Inc. | 9 | $174 |
| Sanofi-aventis U.S. LLC | 10 | $156 |
| Corcept Therapeutics | 3 | $97 |
| Dexcom, Inc. | 5 | $75 |
| Merck | 5 | $70 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Amarin Pharma, Inc. | 3 | $60 |
| Biogen | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Exact Sciences | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Paratek Pharmaceuticals, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Medicure Pharma Inc. | 1 | $26 |
| Bausch Health US, LLC | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Exeltis, USA Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Optinose US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,428 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $87,361 |
| JardianceEmpagliflozin | 41 | $47,260 |
| RybelsusSemaglutide | 26 | $30,447 |
| EliquisApixaban | 36 | $27,405 |
| TrulicityDulaglutide | 14 | $24,425 |
| FarxigaDapagliflozin Propanediol | 21 | $22,640 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $12,247 |
| MounjaroTirzepatide | 12 | $12,231 |
| XareltoRivaroxaban | 14 | $12,174 |
| MyrbetriqMirabegron | 19 | $12,008 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,939 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,830 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $6,616 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $5,771 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $907 | $117,80892 claims |
| Boehringer IngelheimJardiance, Glyxambi | $375 | $53,87552 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $852 | $36,65726 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $558 | $30,47133 claims |
| PfizerEliquis | $503 | $27,40536 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $14 | $18,37341 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $156 | $12,24718 claims |
| Johnson & JohnsonXarelto | $27 | $12,17414 claims |
| Astellas Pharma US IncMyrbetriq | $462 | $12,00819 claims |
| AbbVieSynthroid | $1,035 | $1,37825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Lincoln
- Allen HuntLincoln$17.2M
- Michael IsraelLincoln$375K
- Randy KohlLincoln$67K
- Matthew GlennLincoln$17K
- Uma NookaLincoln$12K
- Kylie ParshallLincoln$12K
- Michael HuffmanLincoln$11K
- Svjetlana DzikoLincoln$11K
- Eric JohnsonLincoln$10K
- Gary van ErtLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.